In colorectal cancer cell lines with different levels of HER2 protein expression (without HER2/neu gene amplification), Takegawa et al., observed that HER2-overexpressing cells were sensitive to T-DXd, but not to other anti-HER2 agents [19]. Here, ERBB2 is linked to colorectal cancer.